BlincytoActive Ingredient(s): Blinatumomab
FDA Approved: * December 3, 2014
Pharm Company: * AMGEN
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In Decembe... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.